Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Katowice – page 95

1 177 clinical trials in Katowice, Poland across 18 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Katowice at a glance
1 177
clinical trials
  • Research sites18
Type of trial
Recruitment status
Quick filters

1 177 trials in Katowice

Open in trial search

Tourette's disorder

Not recruiting

Study on the Effects of Ecopipam Hydrochloride for Children and Adolescents with Tourette's Disorder

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Ecopipam Hydrochloride
  • Sponsor:Emalex Biosciences Inc.

Study on the Safety and Effectiveness of RGN-259 Eye Drops for Patients with Neurotrophic Keratopathy

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Regentree LLC

Study of Pembrolizumab as Additional Treatment for Patients with Liver Cancer (Hepatocellular Carcinoma) After Surgery or Local Ablation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+2

Not recruiting

Comparing inavolisib plus fulvestrant versus alpelisib plus fulvestrant in patients with advanced hormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:F. Hoffmann-La Roche AG

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Study of Chemotherapy With Pembrolizumab and Olaparib for Patients With Advanced Epithelial Ovarian Cancer Without BRCA Mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Colitis ulcerative

Not recruiting

Study on the Safety and Effectiveness of ABBV-668 for Adults with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-668
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer

Not recruiting

Study of Navtemadlin as Maintenance Therapy for Patients with Advanced or Recurrent Endometrial Cancer After Chemotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Loperamide
  • Sponsor:Kartos Therapeutics Inc.

Polycythaemia vera

Not recruiting

Study of SLN124 for Patients with Polycythemia Vera

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Sponsor:Silence Therapeutics PLC

Malignant melanoma

Not recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Stage II-IV Melanoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Diabetic neuropathy

Not recruiting

Study on GSK3858279 for Adults with Chronic Diabetic Nerve Pain

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:GSK3858279
  • Sponsor:Glaxosmithkline Research & Development Limited

Tourette's disorder

Not recruiting

Study on the Long-Term Safety of Ecopipam Hydrochloride Tablets for Children, Adolescents, and Adults with Tourette's Disorder

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ecopipam Hydrochloride
  • Sponsor:Emalex Biosciences Inc.

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Katowice

What the registry says about research in the country

01 Respiratory Conditions

Research focusing on respiratory health conditions, including studies on RSV infections in older adults and treatments for chronic obstructive pulmonary disease. Current trials are evaluating new vaccines and investigating innovative therapies for chronic rhinosinusitis.

  • RSV Vaccine Studies
  • COPD Treatment Evaluation
  • Chronic Rhinosinusitis Management
02 Neurological Disorders

Innovative research into neurodegenerative conditions, with a particular focus on Parkinson's disease treatments. Studies are examining new therapeutic approaches and investigating targeted treatments for early-stage Parkinson's.

  • Early Parkinson's Disease Interventions
  • LRRK2-Driven Parkinson's Research
  • Generalized Myasthenia Gravis Treatment
03 Dermatological Conditions

Comprehensive studies on inflammatory skin conditions, including trials for moderate to severe plaque psoriasis, genital psoriasis, and atopic dermatitis. Research focuses on evaluating new biological treatments and innovative therapies.

  • Plaque Psoriasis Treatments
  • Atopic Dermatitis Management
  • Novel Therapeutic Approaches
04 Oncology and Hematology

Advanced research in cancer treatment, particularly focusing on blood cancers and prostate cancer. Studies include innovative approaches for treating diffuse large B-cell lymphoma and acute myeloid leukemia.

  • Lymphoma Therapies
  • Leukemia Treatments
  • Prostate Cancer Management
05 Autoimmune Conditions

Research investigating treatments for various autoimmune disorders, including Sjögren's Syndrome and chronic inflammatory demyelinating polyneuropathy. Studies focus on evaluating new therapeutic agents and their long-term effectiveness.

  • Sjögren's Disease Therapies
  • CIDP Treatment Approaches
  • Inflammatory Disease Management
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.